Cost-effectiveness of tenofovir disoproxil fumarate prophylaxis for perinatal hepatitis B virus prevention in Ethiopia: a decision analytical modeling

Cost-effectiveness of tenofovir disoproxil fumarate prophylaxis for perinatal hepatitis B virus prevention in Ethiopia: a decision analytical modeling

Abstract Background Perinatal transmission of hepatitis B virus (HBV) remains a significant public health issue. To complement vaccination, tenofovir disoproxil fumarate (TDF) prophylaxis is recommended for HBV-infected pregnant women. We aimed to identify a cost-effective strategy for using TDF to...

Full description

Saved in:

Bibliographic Details
Main Authors:	Abdi Gari Negasa, Firew Tekle Bobo, Desalegn Feleke Falta, Temesgen Kabeta Chala, Negalign Berhanu Bayou
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Series:	BMC Public Health
Subjects:	Cost-effectiveness Hepatitis B MTCT Perinatal Tenofovir Ethiopia
Online Access:	https://doi.org/10.1186/s12889-025-22498-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01)

Factors Affecting Rapid Decline in Glomerular Filtration Rate in HIV/AIDS Patients Using Tenofovir Disoproxil Fumarate
by: Prima Yuriandro, et al.
Published: (2019-09-01)

Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review
by: Iulia Baciu, et al.
Published: (2021-02-01)

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate
by: Hamed Mirmoezzi, et al.
Published: (2025-03-01)

Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
by: Ris Raihan Felim, et al.
Published: (2024-10-01)

Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
by: Ris Raihan Felim, et al.
Published: (2024-07-01)

Evaluation of Hippocampal Microanatomy and Neuro-Biomarkers Following Administration of Silver Nanoparticles Conjugated with Tenofovir Disoproxil Fumarate in Experimental Diabetic Rats
by: Sodiq Kolawole Lawal, et al.
Published: (2024-12-01)

Tenofovir disoproxil fumarate versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis
by: Yong Wang, et al.
Published: (2025-05-01)

Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial
by: Jun Chen, et al.
Published: (2020-01-01)

Factors predicting renal impairment associated with Tenofovir Disoproxil fumarate: Focus on patients with HIV and pre-existing metabolic abnormalities under the Thai National Health Security Scheme
by: Duangjai Duangrithi, et al.
Published: (2025-08-01)

A cross‐sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV‐1 in tenofovir disoproxil fumarate‐based pre‐exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa
by: Urvi M. Parikh, et al.
Published: (2025-08-01)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
by: Derek E. Murrell, et al.
Published: (2025-05-01)

Novel Micro-LC-MS/MS Method for the Quantification of Tenofovir and Its Active Metabolite Tenofovir-Diphosphate in Biological Matrices for Therapeutic Drug Monitoring
by: Isabela Tarcomnicu, et al.
Published: (2025-06-01)

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir
by: Aaminat Qureshi, et al.
Published: (2022-07-01)

Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study
by: Xinye Qiu, et al.
Published: (2025-04-01)

Primary partial response with tenofovir monotherapy: two adults and one child
by: Habip Gedik
Published: (2022-05-01)

Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required.
by: Giuseppe Vittorio De Socio, et al.
Published: (2012-01-01)

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
by: Hyung Joon Yim, et al.
Published: (2025-07-01)

The impact of adherence counseling incorporating a point of care urine tenofovir assay on virologic suppression among individuals failing tenofovir-lamivudine-dolutegravir: A pre-post intervention study
by: Leonard Bikinesi, et al.
Published: (2025-02-01)

Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B
by: Beatriz López Centeno, et al.
Published: (2016-07-01)

Tenofovir as Rescue Therapy Following Clinical Failure to Lamivudine in Severe Acute Hepatitis B
by: Jurgen Gerada, et al.
Published: (2013-06-01)

Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia
by: Rino Alvani Gani
Published: (2018-09-01)

In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa
by: Kerusha Reddy, et al.
Published: (2024-11-01)

Efficacy of tenofovir on clinical outcomes of COVID-19 patients: a systematic review
by: Thaís Lorenna Souza Sales, et al.
Published: (2025-07-01)

Factors driving decisions in the use of HIV pre-exposure prophylaxis: a real-world study in the United States
by: Yohance Whiteside, et al.
Published: (2024-12-01)

Screening for HBV, HCV, TP and HIV in pregnant women from various ethnic groups in Yili, Xinjiang, China
by: Zhenzhen Pan, et al.
Published: (2025-04-01)

Effect of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamideantiviral Therapy on Renal Function in Chronic Hepatitis B Patients: A Real-World Retrospective Study
by: Li Y, et al.
Published: (2025-02-01)

Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis
by: Lu Chen, et al.
Published: (2025-08-01)

Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.
by: Yi Lin, et al.
Published: (2025-01-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
by: Freeman W Chabala, et al.
Published: (2021-01-01)

Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China
by: Wang W, et al.
Published: (2025-05-01)

Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
by: Takuya Matsubara, et al.
Published: (2025-01-01)

Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis
by: Tegene Legese Dadi, et al.
Published: (2017-01-01)

Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in HIV treatment: a real-world single-center study in China
by: Aixin Li, et al.
Published: (2025-05-01)

Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks
by: Willington Amutuhaire, et al.
Published: (2025-01-01)

Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks.
by: Willington Amutuhaire, et al.
Published: (2025-01-01)

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia
by: Gashaw Sisay Chanie, et al.
Published: (2025-04-01)